var data={"title":"Amikacin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amikacin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5608?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">see &quot;Amikacin: Drug information&quot;</a> and <a href=\"topic.htm?path=amikacin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amikacin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708619\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ototoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurotoxicity, manifested as vestibular and permanent bilateral auditory ototoxicity, can occur in patients with preexisting renal damage and in patients with normal renal function treated at higher doses and/or periods longer than those recommended. The risk of aminoglycoside-induced ototoxicity is greater in patients with renal damage. High frequency deafness usually occurs first and can be detected only by audiometric testing. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of hearing loss due to aminoglycosides increases with the degree of exposure to either high peak or high trough serum concentrations. Patients developing cochlear damage may not have symptoms during therapy to warn them of developing eighth-nerve toxicity, and total or partial irreversible bilateral deafness may occur after the drug has been discontinued. Aminoglycoside-induced ototoxicity is usually irreversible. Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential ototoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\"> Aminoglycosides are potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high doses or prolonged therapy. Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential nephrotoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuromuscular blockade:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical instillation (as in orthopedic and abdominal irrigation or in local treatment of empyema), and following oral use of aminoglycosides. The possibility of these phenomena should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but mechanical respiratory assistance may be necessary.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal and eighth-nerve function should be closely monitored especially in patients with known or suspected renal impairment at the onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Serum concentrations of amikacin should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels and prolonged peak concentrations above 35 mcg/mL. Urine should be examined for decreased specific gravity, increased excretion of proteins, and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained where feasible in patients old enough to be tested, particularly high-risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires discontinuation of the drug or dosage adjustment.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent and/or sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent use of amikacin with potent diuretics (ethacrynic acid, or furosemide) should be avoided because diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132946\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Amikacin Sulfate Injection, USP;</li>\n      <li>Amikin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045015\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Aminoglycoside</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431469\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing strategies may vary by institution as a wide variety of dosing regimens have been studied (Allegaert 2006; Allegaert 2008; Labaune 2001; Sherwin 2009). Dosage should be based on actual weight unless the patient has hydrops fetalis. <b>Note:</b> Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing; susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Age-directed dosing (Bradley 2016): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gestational age &lt;30 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;14 days: 15 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;15 days: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gestational age 30 to 34 weeks, PNA &le;60 days: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gestational age &ge;35 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &ge;8 days: 17.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing (<i>Red Book</i> (AAP 2015]): IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;14 days: 15 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 15 to 28 days: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 15 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA &le;7 days: 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PNA 8 to 28 days: 17.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> IV: <b>Note:</b> Use smaller doses and longer intervals for neonates &lt;2 kg (Tunkel 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &le;7 days and &ge;2 kg: 15 to 20 mg/kg/<b>day</b> divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &gt;7 days and &ge;2 kg: 30 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Consider single-dose administration with serum concentration monitoring in patients with urine output &lt;1 mL/kg/hour or serum creatinine &gt;1.3 mg/dL rather than scheduled dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045008\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">see &quot;Amikacin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosage should be based on an estimate of ideal body weight. In morbidly obese children and adolescents, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW). Initial dosing recommendation presented; dosage should be individualized based upon serum concentration monitoring. Initial and periodic plasma drug concentrations (eg, peak and trough with conventional dosing, post dose level at a prespecified time with extended-interval dosing) should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, severe, susceptible infections:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 15 to 22.5 mg/kg/<b>day</b> divided every 8 hours <b>or</b> 15 to 20 mg/kg/dose every 24 hours (<i>Red Book</i> [AAP 2015]);</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis (Tunkel 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 20 to 30 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 15 mg/kg/<b>day</b> divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VP-shunt infection, ventriculitis: Limited data available: Intraventricular/intrathecal <b>(use a preservative-free preparation)</b>: Infants, Children, and Adolescents: 5 to 50 mg/<b>day</b>; usual dose: 30 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis, pulmonary infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Traditional dosing: IV, IM: 10 mg/kg/dose every 8 hours (Wallace 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-interval dosing: IV: 30 mg/kg/dose every 24 hours (Flume 2009); <b>Note:</b> The CF Foundation recommends extended-interval dosing as preferred over traditional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b> Children and Adolescents: IV: 15 mg/kg/day divided every 8 to 12 hours; use in combination with other antibiotics dependent upon organism and source of infection (ie, valve-type) (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 15 to 22.5 mg/kg/day divided every 8 to 24 hours (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mycobacterium, avium complex infection (MAC), treatment: </b>HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV: 15 to 30 mg/kg/<b>day</b> divided every 12 to 24 hours as part of a multiple drug regimen; maximum daily dose: 1,500 mg/<b>day</b> (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: 10 to 15 mg/kg/dose every 24 hours as part of a multiple drug regimen; maximum daily dose: 1,500 mg/<b>day</b> (HHS [OI adult 2016]; HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis, drug-resistant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &le;14 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once-daily regimen: IM, IV: 15 to 20 mg/kg/dose once daily as part of a multiple drug regimen (ATS/CDC/IDSA [Nahid 2016]); current guidelines do not provide a maximum daily dose; for HIV-exposed/-positive pediatric patients, a maximum daily dose of 1,000 mg/<b>day</b> has been suggested for similar mg/kg doses (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Twice-<b>weekly</b> regimen: IM, IV: 25 to 30 mg/kg/dose administered twice <b>weekly</b> as part of a multiple drug regimen; dosing based on experience in adult patients and pediatric pharmacokinetic considerations (ATS/CDC/IDSA [Nahid 2016]); current guidelines do not provide a maximum daily dose; for HIV-exposed/-positive pediatric patients, a maximum daily dose of 1,000 mg/<b>day</b> has been suggested for similar mg/kg doses (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive: IM, IV: 15 to 30 mg/kg/dose once daily as part of a multiple drug regimen; maximum daily dose: 1,000 mg/<b>day</b> (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years: Independent of HIV status:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once-daily regimen: IM, IV: 15 mg/kg/dose once daily as part of a multiple drug regimen (ATS/CDC/IDSA [Nahid 2016]; HHS [OI adult 2016]); current guidelines do not provide a maximum daily dose; for HIV-exposed/-positive pediatric patients, a maximum daily dose of 1,000 mg/<b>day</b> has been suggested for similar mg/kg doses (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Three-times-<b>weekly</b> regimen: IM, IV: 25 mg/kg/dose 3 times <b>weekly </b>(ATS/CDC/IDSA [Nahid 2016]; HHS [OI adult 2016]). Current guidelines do not provide a maximum dose; for HIV-exposed/-positive pediatric patients, a maximum daily dose of 1,000 mg/<b>day</b> has been suggested for similar mg/kg doses (HHS [OI pediatric 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (CAPD):</b> Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 25 mg per liter of dialysate; maintenance dose: 12 mg per liter (Warady 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Individualization is critical because of the low therapeutic index. In underweight and nonobese patients, use of total body weight (TBW) instead of ideal body weight for determining the initial mg/kg/dose is widely accepted (Nicolau 1995). Ideal body weight (IBW) also may be used to determine doses for patients who are neither underweight nor obese (Gilbert 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial and periodic peak and trough plasma drug levels should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Manufacturer recommends a maximum daily dose of 15 mg/kg/<b>day</b> (or 1,500 mg/<b>day</b> in heavier patients). Higher doses may be warranted based on therapeutic drug monitoring or susceptibility information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage range:</b> IM, IV: 5 to 7.5 mg/kg/dose every 8 hours; <b>Note:</b> Some clinicians suggest a daily dose of 15 to 20 mg/kg/day for all patients with normal renal function. This dose is at least as efficacious with similar, if not less, toxicity than conventional dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis (susceptible gram-negative organisms):</b> IV: 5 mg/kg every 8 hours (administered with another bacteriocidal drug) (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium fortuitum</i>, <i>M. chelonae</i>, or <i>M. abscessus</i>:</b> IV: 10 to 15 mg/kg daily for at least 2 weeks with high-dose cefoxitin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing interval in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended (Aronoff 2007); <b>Note:</b> Renally adjusted dose recommendations are based on doses of 5 to 7.5 mg/kg/dose every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis: 5 mg/kg/dose; redose as indicated by serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD):  5 mg/kg/dose; redose as indicated by serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): 7.5 mg/kg/dose every 12 hours, monitor serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: <b>Note:</b> Some patients may require larger or more frequent doses if serum levels document the need (ie, cystic fibrosis or febrile granulocytopenic patients)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended: <b>Note: </b>Renally adjusted dose recommendations are based on a dose of 7.5 mg/kg every 12 hours or 15 mg/kg every 24 hours (Aronoff 2007).</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">GFR &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">GFR 10 to 50 mL/minute: Administer every 24 to 72 hours based on serum concentrations</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">GFR &lt;10 mL/minute: Administer every 48 to 72 hours based on serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20%; variable; dependent on filter, duration, and type of HD): 5 to 7.5 mg/kg every 48 to 72 hours. Follow levels. Redose when pre-HD serum concentration &lt;10 mg/L; redose when post-HD serum concentration &lt;6 to 8 mcg/mL (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH/CVVHD/CVVHDF: Loading dose of 10 mg/kg followed by maintenance dose of 7.5 mg/kg every 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For severe gram-negative rod infections, target peak serum concentration of 15 to 30 mcg/mL; redose when serum concentration &lt;10 mcg/mL (Heintz 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132922\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/2 mL (2 mL); 1 g/4 mL (4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg/2 mL (2 mL); 1 g/4 mL (4 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132905\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045020\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer around-the-clock to promote less variation in peak and trough serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer undiluted into a large muscle mass. Slower absorption and lower peak concentrations, probably due to poor circulation in the atrophic muscle, may occur following IM injection; in paralyzed patients, suggest IV route</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermittent IV infusion: Infuse over 30 to 60 minutes; in infants infusion over 1 to 2 hours is recommended by the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides in vitro. This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy in vivo, particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132940\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Following admixture at concentrations of 0.25 to 5 mg/mL in D5W, NS, D5<sup>1</sup>/<sub>4</sub>NS,  D5<sup>1</sup>/<sub>2</sub>NS,    LR, Normosol M in D5W, Normosol R in D5, Plasma-Lyte 56 in D5 or Plasma-Lyte 148 in D5W, amikacin is stable for 24 hours at room temperature, 60 days at 4&deg;C (39&deg;F), or 30 days at -15&deg;C (5&deg;F). Previously refrigerated or thawed frozen solutions are stable for 24 hours when stored at 25&deg;C (77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045019\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of serious infections (bone and respiratory infections, endocarditis, and septicemia) due to organisms resistant to gentamicin and tobramycin, including <i>Pseudomonas</i>, <i>Klebsiella</i>, <i>Enterobacter</i>, <i>Serratia</i>, <i>Proteus</i>, and <i>Providencia</i> species, and <i>E. coli</i> (FDA approved in all ages); has also been used for documented infection of susceptible mycobacterial organisms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132998\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amikacin may be confused with Amicar, anakinra </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amikin may be confused with Amicar, Kineret</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132995\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Central nervous system: Neurotoxicity </p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Genitourinary: Nephrotoxicity </p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Otic: Auditory ototoxicity, vestibular ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Dyspnea, eosinophilia, hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132930\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132910\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Cross-sensitivity to other aminoglycosides may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis:<b> [US Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis; </b> especially when given soon after anesthesia or muscle relaxants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity; </b>usual risk factors include preexisting renal impairment, concomitant neuro-/nephrotoxic medications, advanced age and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypocalcemia: Use with caution in patients with hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis or parkinsonism. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal insufficiency; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxic and/or nephrotoxic drugs:<b> [US Boxed Warning]: Avoid concomitant or sequential use of other neurotoxic and/or nephrotoxic drugs (eg, bacitracin, cisplatin, amphotericin B, paromomycin, polymyxin B, colistin, vancomycin, other aminoglycosides).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Potent diuretics: <b>[US Boxed Warning]: Avoid concomitant use with potent diuretics (eg, ethacrynic acid, furosemide) since diuretics themselves may cause ototoxicity and may enhance aminoglycoside toxicity.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfites: May contain sulfites which may cause allergic-type reactions (including anaphylaxis) as well as life-threatening or less severe asthmatic episodes in certain individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgical irrigation: Irreversible deafness, renal failure, and death due to neuromuscular blockade have been reported following use of aminoglycosides as surgical irrigation; rapid systemic absorption occurs with topical application (except to the urinary bladder).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819739\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298732\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132915\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12541&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132918\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5722003\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events were not observed in the initial animal reproduction studies. Amikacin crosses the placenta and produces detectable concentrations in the fetus. Aminoglycosides may cause fetal harm if administered to a pregnant woman. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of amikacin may be altered (Bernard 1977). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045014\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, urine output, BUN, serum creatinine, peak and trough serum amikacin concentrations; be alert to ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">With conventional dosing, typically obtain serum concentration after the third dose; exceptions for earlier monitoring may include neonates or patients with rapidly changing renal function. With extended-interval dosing, usually obtain serum concentration after first, second, or third dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Not all infants and children who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Treatment course &gt;5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients with decreased or changing renal function</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients with poor therapeutic response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates and Infants &lt;3 months of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atypical body constituency (obesity, expanded extracellular fluid volume)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clinical need for higher doses or shorter intervals (eg, cystic fibrosis, burns, endocarditis, meningitis, critically ill patients, relatively resistant organisms)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients on hemodialysis or chronic ambulatory peritoneal dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Signs of nephrotoxicity or ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant use of other nephrotoxic agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045018\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Therapeutic levels:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Life-threatening infections: 25 to 40 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serious infections: 20 to 25 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urinary tract infections: 15 to 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Trough: &lt;8 mcg/mL; the American Thoracic Society (ATS) recommends trough levels of &lt;4 to 5 mcg/mL for patients with hospital-acquired pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Timing of serum samples: Draw peak 30 minutes after completion of 30-minute infusion or at 1 hour following initiation of infusion or IM injection; draw trough within 30 minutes prior to next dose; aminoglycoside levels measured from blood taken from Silastic central catheters can sometimes give falsely elevated readings</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132909\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits protein synthesis in susceptible bacteria by binding to 30S ribosomal subunits</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132929\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Poorly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.25 L/kg (Vozeh 1988); primarily into extracellular fluid (highly hydrophilic); poor penetration into the blood-brain barrier even when meninges are inflamed; V<sub>d</sub> is increased in neonates and patients with edema, ascites, fluid overload; V<sub>d</sub> is decreased in patients with dehydration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relative diffusion of antimicrobial agents from blood into CSF: Good only with inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF:blood level ratio: Infants: Normal meninges: 10% to 20%; Inflamed meninges: up to 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein-binding: 0% to 11%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (renal function and age dependent):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: Low birth weight (1 to 3 days): 7 to 9 hours; Full-term &gt;7 days: 4 to 5 hours (Howard 1975)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 1.6 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 1.5 &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Normal renal function: ~2 hours; Anuria/end-stage renal disease: 17 to 150 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 60 minutes; IV: Within 30 minutes following a 30-minute infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (94% to 98% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322981\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amikacin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/4 mL (4 mL): $18.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/2 mL (2 mL): $9.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132935\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acemycin (TW);</li>\n      <li>Agnicin (MX);</li>\n      <li>Akacin (MX, TH);</li>\n      <li>Akamigis (VN);</li>\n      <li>Akicin (TH);</li>\n      <li>Akim (EC);</li>\n      <li>Alostil (ID);</li>\n      <li>Amibiotic (UA);</li>\n      <li>Amicacina (ES);</li>\n      <li>Amicare (PH);</li>\n      <li>Amicasil (IT);</li>\n      <li>Amicilon (BR);</li>\n      <li>Amicin (IN);</li>\n      <li>Amikabiot (PE);</li>\n      <li>Amikacin Fresenius (DE);</li>\n      <li>Amikacina (CL);</li>\n      <li>Amikacina Normon (PT);</li>\n      <li>Amikafur (MX);</li>\n      <li>Amikagram (PE);</li>\n      <li>Amikan (IT);</li>\n      <li>Amikaxing (CN);</li>\n      <li>Amikayect (MX);</li>\n      <li>Amikin (BD, BF, BJ, CH, CI, CO, CZ, EC, EE, EG, ET, GB, GH, GM, GN, HK, IE, JO, KE, KR, KW, LR, MA, ML, MR, MT, MU, MW, NE, NG, NZ, PE, PK, PL, QA, SA, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Amikin. (MX);</li>\n      <li>Amiklin (FR);</li>\n      <li>Amikozit (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, RO, RU, SA, SY, TR, YE);</li>\n      <li>Amiktam (KR);</li>\n      <li>Amiosin (ID);</li>\n      <li>Amitax (PH);</li>\n      <li>Amitsyl (UA);</li>\n      <li>Ampro (LK);</li>\n      <li>Amukin (BE, LU, NL);</li>\n      <li>Apalin (MY);</li>\n      <li>Biclin (MX, PT);</li>\n      <li>Biklin (AR, AT, DE, FI, SE, VE);</li>\n      <li>Biodacyna (LT);</li>\n      <li>Biokacin (MX, PY);</li>\n      <li>Biomikin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Briclin (UY);</li>\n      <li>Briklin (GR);</li>\n      <li>Chemacin (IT);</li>\n      <li>Cinamak (BD);</li>\n      <li>Cinmik (PH);</li>\n      <li>Eukacin (TW);</li>\n      <li>Flekselit (UA);</li>\n      <li>Gamikal (MX);</li>\n      <li>Glukamin (EC);</li>\n      <li>Glybotic (ID);</li>\n      <li>Indobact (PY);</li>\n      <li>Kacin (BD);</li>\n      <li>Kacinth-A (ZA);</li>\n      <li>Kamicin (ET);</li>\n      <li>Kamin (PH);</li>\n      <li>Kamina (PT);</li>\n      <li>Karmikin (MX);</li>\n      <li>Kormakin (PH);</li>\n      <li>Lanomycin (GR);</li>\n      <li>Likacin (AE, BH, CY, EG, HU, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, VN, YE);</li>\n      <li>Likacin Gel (TH);</li>\n      <li>Lisobac (MX);</li>\n      <li>Lorikatsyn (UA);</li>\n      <li>Lukadin (IT);</li>\n      <li>Miacin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Mikaciland (PY);</li>\n      <li>Mikacin (AE, BD, BH, KW, QA, SA);</li>\n      <li>Mikaject (ID);</li>\n      <li>Mikasin (ID);</li>\n      <li>Mikin (KR);</li>\n      <li>Nicin (LK);</li>\n      <li>Oprad (MX);</li>\n      <li>Orlobin (GR, MT);</li>\n      <li>Psudonil (BD);</li>\n      <li>Ramickin (KR);</li>\n      <li>Riklinak (AR);</li>\n      <li>Savox (TW);</li>\n      <li>Selaxa (GR);</li>\n      <li>Selemycin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Sikacin (TW);</li>\n      <li>Simikan (ID);</li>\n      <li>Tybikin (TH);</li>\n      <li>Uzix (GR, MT);</li>\n      <li>Verdix (ID);</li>\n      <li>Vijomikin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Yectamid (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allegaert K, Anderson BJ, Cossey V, et al, &quot;Limited Predictability of Amikacin Clearance in Extreme Premature Neonates at Birth,&quot; <i>Br J Clin Pharmacol</i>, 2006, 61(1):39-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/16390350/pubmed\" target=\"_blank\" id=\"16390350\">16390350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allegaert K, Scheers I, Cossey V, et al, &quot;Covariates of Amikacin Clearance in Neonates: The Impact of Postnatal Age on Predictability,&quot; <i>Drug Metab Lett</i>, 2008, 2(4):286-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/19356107/pubmed\" target=\"_blank\" id=\"19356107\">19356107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society and Infectious Diseases Society of America, &quot;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&quot; <i>Am J Respir Crit Care Med. </i>2005; 171(4):388-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/15699079/pubmed\" target=\"_blank\" id=\"15699079\">15699079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amikacin injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernard B, Abate M, Thielen PF, et al, &quot;Maternal-Fetal Pharmacological Activity of Amikacin,&quot; <i>J Infect Dis</i>, 1977, 135(6):925-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/864287/pubmed\" target=\"_blank\" id=\"864287\">864287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 22nd ed. American Academy of Pediatrics; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engle WA and American Academy of Pediatrics Committee on Fetus and Newborn, &quot;Age Terminology During the Perinatal Period,&quot; <i>Pediatrics</i>, 2004, 114(5):1362-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/15520122/pubmed\" target=\"_blank\" id=\"15520122\">15520122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flume PA, Mogayzel PJ Jr, Robinson KA, et al, &quot;Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,&quot; <i>Am J Respir Crit Care Med</i>, 2009, 180(9):802-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/19729669/pubmed\" target=\"_blank\" id=\"19729669\">19729669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, Leggett JE. &quot;Aminoglycosides,&rdquo; Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed, Chapter 26, Mandell GL, Bennett JE, and Dolin R, eds, Philadelphia, PA: Churchill Linvingstone Elsevier, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert VE, Beals JD Jr, Natelson SE, et al, &quot;Treatment of Cerebrospinal Fluid Leaks and Gram-Negative Bacillary Meningitis With Large Doses of Intrathecal Amikacin and Systemic Antibiotics,&quot; <i>Neurosurgery</i>, 1986, 18(4):402-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/3754626/pubmed\" target=\"_blank\" id=\"3754626\">3754626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, and Dager WE, &quot;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&quot; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard JB, McCracken GH. &quot;Pharmacological evaluation of Amikacin in Neonates.&quot; <i>Antimicrob Agents Chemother</i>. 1975; 8(1):86-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/1164009/pubmed\" target=\"_blank\" id=\"1164009\">1164009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Sinaniotis CA, Papadatos CJ, Kosmidis J. Pharmacokinetics of amikacin in infants and pre-school children. <i>Acta Paediatr Scand</i>. 1979;68(3):419-422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/443042 /pubmed\" target=\"_blank\" id=\"443042 \">443042 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kasiakou SK, Rafailidis PI, Liaropoulos K, et al, &quot;Cure of Post-Traumatic Recurrent Multiresistant Gram-Negative Rod Meningitis With Intraventricular Colistin,&quot; <i>J Infect</i>, 2005, 50(4):348-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/15845435/pubmed\" target=\"_blank\" id=\"15845435\">15845435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kenyon CF, Knoppert DC, Lee SK, et al, &ldquo;Amikacin Pharmacokinetics and Suggested Dosage Modifications for the Preterm Infant,&rdquo; <i>Antimicrob Agents Chemother</i>, 1990, 34(2):265-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/2327775/pubmed\" target=\"_blank\" id=\"2327775\">2327775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Labaune JM, Bleyzac N, Maire P, et al, &quot;Once-a-Day Individualized Amikacin Dosing for Suspected Infection at Birth Based on Population Pharmacokinetic Models,&quot; <i>Biol Neonate</i>, 2001, 80(2):142-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/11509814/pubmed\" target=\"_blank\" id=\"11509814\">11509814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. <i>Perit Dial Int</i>. 2010;30(4):393-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/20628102/pubmed\" target=\"_blank\" id=\"20628102\">20628102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsuda S, &quot;Transfer of Antibiotics Into Maternal Milk,&quot; <i>Biol Res Pregnancy Perinatol</i>, 1984, 5(2):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/6743732/pubmed\" target=\"_blank\" id=\"6743732\">6743732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. <i>Antimicrob Agents Chemother</i>. 1995;39(3):650-655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/7793867/pubmed\" target=\"_blank\" id=\"7793867\">7793867</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Service Task Force on Prophylaxis and Therapy for <i>Mycobacterium avium</i> Complex, &ldquo;Recommendations on Prophylaxis and Therapy for Disseminated <i>Mycobacterium avium</i> Complex Disease in Patients Infected With the Human Immunodeficiency Virus,&rdquo; <i>N Engl J Med</i>, 1993, 329(12):898-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/8395019/pubmed\" target=\"_blank\" id=\"8395019\">8395019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodr&iacute;guez Guardado A, Blanco A, Asensi V, et al, &quot;Multidrug-Resistant Acinetobacter Meningitis in Neurosurgical Patients With Intraventricular Catheters: Assessment of Different Treatments,&quot; <i>J Antimicrob Chemother</i>, 2008, 61(4):908-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/18281693/pubmed\" target=\"_blank\" id=\"18281693\">18281693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sherwin CM, Svahn S, Van der Linden A, et al, &quot;Individualised Dosing of Amikacin in Neonates: A Pharmacokinetic/Pharmacodynamic Analysis,&quot; <i>Eur J Clin Pharmacol</i>, 2009, 65(7):705-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/19305985/pubmed\" target=\"_blank\" id=\"19305985\">19305985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/7667049 /pubmed\" target=\"_blank\" id=\"7667049 \">7667049 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogelstein B, Kowarski A, and Lietman PS, &ldquo;The Pharmacokinetics of Amikacin in Children,&rdquo; <i>J Pediatr</i>, 1977, 91(2):333-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/874697/pubmed\" target=\"_blank\" id=\"874697\">874697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, Taeschner W. Pharmacokinetic drug data. <i>Clin Pharmacokinet</i>. 1988;15(4):254-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace CS, Hall M, Kuhn RJ. Pharmacologic management of cystic fibrosis. <i>Clin Pharm</i>. 1993;12(9):657-674.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amikacin-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12541 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708619\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132946\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045015\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431469\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045008\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132922\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F132905\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045020\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F132940\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045019\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132998\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132995\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132930\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132910\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819739\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298732\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132915\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132918\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5722003\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045014\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1045018\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132909\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F132929\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322981\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132935\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12541|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">Amikacin: Drug information</a></li><li><a href=\"topic.htm?path=amikacin-patient-drug-information\" class=\"drug drug_patient\">Amikacin: Patient drug information</a></li></ul></div></div>","javascript":null}